wellrank.ai
Effexor logo

Effexor

First cited by AI Jun 11, 2026
effexorvenlafaxine.com

Surfaced organically in AI answers about menopause and women's health. Not yet profiled.

AI Visibility

Visibility trend

Menopause and women's health, daily share of AI answers mentioning Effexor, through Jun 13, 2026.

8.3%

Avg position when mentioned: 3.0

By engine

Where Effexor is strong, and where it is invisible.

  • Claude
    33.3%

Mention sentiment

Tone of AI mentions across all tracked answers.

  • 2 positive mentions
  • 1 neutral
  • 0 mixed or cautious

Recent AI answers mentioning Effexor

ClaudeJun 13, 2026, 11:06 UTC
What is the best non hormonal treatment for hot flashes?

Best Non-Hormonal Treatments for Hot Flashes Prescription Options Veozah (fezolinetant) - FDA-approved specifically for hot flashes; blocks brain receptors that trigger them. Very effective and relatively new (2023) Brisdelle (paroxetine 7.5mg) - the only FDA-approved SSRI for hot flashes Effexor (venlafaxine) - widely used off-label, well-studied for hot flash relief Over-the-Counter Supplements Remifemin (Black Cohosh) - most studied herbal option with decent evidence Bonafide Relizen - plant pollen extract with good clinical backing and no phytoestrogens Estroven - popular blend containing black cohosh, widely available Lifestyle Tools Embr Wave - wristband that uses temperature therapy to reduce hot flash intensity Chill Factor cooling towels/pillows for nighttime symptoms Key Recommendations Veozah is considered the most effective non-hormonal prescription option currently available Bonafide Relizen is a top OTC choice because it's estrogen-free and clinically tested Talk to your doctor before starting any treatment, especially prescriptions Would you like more detail on any of these options?

Mentioned in position 3 of 8

Read full answer with sources →
PerplexityJun 12, 2026, 11:05 UTC
What actually helps with perimenopause symptoms besides hormones?

Besides hormone therapy, several evidence-based and supportive options can help manage perimenopause symptoms (such as hot flashes, night sweats, mood changes, and sleep disturbances). These include: FDA-Approved Non-Hormonal Medications Paroxetine (7.5 mg low-dose): The only SSRI specifically FDA-approved for treating hot flashes and night sweats in women without mood disorders. Fezolinetant (Veozah): A newer FDA-approved neurokinin-3 (NK3) receptor antagonist that directly targets the body’s temperature regulation system to reduce hot flashes. Other SSRIs/SNRIs (used off-label but supported by studies): Escitalopram (Lexapro) Venlafaxine (Effexor) Citalopram (Celexa) Bupropion (Wellbutrin) – may also help with sexual satisfaction. Other Prescription Medications (Off-Label Use) Gabapentin: An anticonvulsant that can reduce hot flash frequency, especially at night. Oxybutynin: Approved for overactive bladder but shown in trials to reduce hot flashes (30–50% improvement); may be especially helpful if you also have urinary symptoms. Modafinil: Some evidence suggests benefit for sleep and fatigue, though research is limited. Mind-Body & Behavioral Therapies Cognitive Behavioral Therapy (CBT): Strong evidence shows CBT reduces the frequency and severity of hot flashes and improves quality of life. Clinical Hypnosis: Demonstrated to reduce hot flash frequency compared to no treatment. Mindfulness-Based Stress Reduction (MBSR): Growing evidence supports its role in lowering hot flash severity. Acupuncture: May help modulate neurotransmitters and reduce hot flashes and insomnia, though effects on estrogen levels are minimal. Lifestyle & Dietary Adjustments Weight Management: Losing excess weight has been linked to reduced hot flash intensity. Dietary Changes: Soy and phytoestrogens (e.g., flaxseed, soy products): May modestly alleviate hot flashes, though results vary. Omega-3 fatty acids (from fish like salmon, sardines, or plant sources like chia and flax): Support cardiovascular, mood, and cognitive health. Sleep Hygiene: Use of white noise machines, calming bedtime routines, aromatherapy (lavender, eucalyptus), and avoiding screens before bed. “Chillows” or handheld fans can help manage body temperature during hot flashes. Supplements (Limited Evidence) While many supplements are marketed for perimenopause, most lack strong evidence and are not more effective than placebo: Black cohosh: Some studies show modest benefit for hot flashes; safety data is mixed. Evening primrose oil: Limited evidence; may help with breast pain in premenopausal women. Ashwagandha, Rhodiola, Magnesium, Omega-3s: May offer general support for mood, stress, or sleep but are not proven to directly treat hot flashes. Note: According to major health organizations (including Harvard, Mayo Clinic, and the Office on Women’s Health), no herb or supplement has been consistently proven superior to placebo for reducing hot flashes and night sweats. Summary: What Actually Works ✅ Strongly Supported: Low-dose paroxetine or fezolinetant (FDA-approved) Other SSRIs/SNRIs (supported by multiple studies) CBT and clinical hypnosis Gabapentin and oxybutynin (off-label but effective) ⚠️ Mildly or Inconsistently Supported: Soy/phytoestrogens, black cohosh, acupuncture, omega-3s Sleep hygiene tools (fans, chillows, aromatherapy) ❌ Not Evidence-Based: Most supplements marketed for hot flashes (e.g., evening primrose, ashwagandha) unless used for general wellness For personalized care, consult a healthcare provider to evaluate symptom severity, medical history, and eligibility for prescription options.

Mentioned in position 3 of 5

Read full answer with sources →
ChatGPTJun 11, 2026, 20:08 UTC
I am 47 with hot flashes and terrible sleep. What are my treatment options?

Short answer If your hot flashes are frequent/intense and they’re what’s wrecking your sleep, menopausal hormone therapy (MHT, i.e., estrogen ± a progestogen) is the single most effective treatment for both vasomotor symptoms and the sleep problems they cause — provided you don’t have contraindications. If you can’t or don’t want hormones, there are effective non‑hormonal drug and behavioral options (antidepressants, gabapentin, CBT‑I, cooling strategies, etc.). Below is a practical, clinician‑friendly summary of options, pros/cons, and specific products/brands to discuss with your doctor. 1) Menopausal hormone therapy (MHT) — most effective What it treats: Hot flashes, night sweats, and related sleep disruption; it often improves mood and vaginal symptoms as well. Who it’s best for: Generally recommended for women with moderate–severe vasomotor symptoms without major contraindications (history of breast cancer, active liver disease, known clotting disorders, recent stroke/heart attack). Regimens/routes: Systemic estrogen (works best for hot flashes): oral (Estrace, Premarin) or transdermal patch/gel. Transdermal estradiol patches/gels (Vivelle‑Dot, Climara, EstroGel) may have lower risk of blood clots than oral estrogen and are often preferred if you have migraine with aura or higher clot risk. If you have a uterus, you also need a progestogen to protect the lining of the uterus: micronized progesterone (Prometrium) or medroxyprogesterone (Provera) are common. Another option is an intrauterine levonorgestrel device (Mirena) for local progestin. Risks: small increased risks of breast cancer with long‑term combined use, and of VTE/stroke (risk varies by age, time since menopause, route of administration). Use the lowest effective dose for the shortest period needed; many women use it for several years with regular re‑evaluation. 2) Non‑hormonal prescription options (if hormones aren’t appropriate or desired) SSRIs/SNRIs: Paroxetine 7.5 mg (Brisdelle) is FDA‑approved for hot flashes. Note: paroxetine and fluoxetine strongly inhibit CYP2D6 and can interfere with tamoxifen — avoid if you’re taking tamoxifen. Venlafaxine (Effexor) and desvenlafaxine are commonly used and effective for hot flashes; can improve sleep in some women. Gabapentin (Neurontin): often used at bedtime (typical effective total daily doses 300–900 mg) and especially helpful for nighttime hot flashes and sleep. Pregabalin (Lyrica) also effective but is a controlled medication and typically considered after others. Clonidine (Catapres): modest benefit, sometimes used if other options fail. Choice depends on comorbidities (anxiety, depression, insomnia), side‑effect profile, and drug interactions. 3) Treatments targeted primarily at sleep Cognitive behavioral therapy for insomnia (CBT‑I) is first‑line for chronic insomnia and effective long term. Digital programs (e.g., Sleepio) or a behavioral sleep specialist are options. Sleep medications for short‑term use: zolpidem (Ambien) or zaleplon; low‑dose doxepin (Silenor) or trazodone are alternatives; ramelteon (Rozerem) is a melatonin receptor agonist. Avoid chronic benzodiazepine/Z‑drug use if possible. Melatonin (over the counter) can help some people with sleep onset. 4) Lifestyle, behavioral, and practical measures Identify and avoid hot‑flash triggers (alcohol, spicy foods, caffeine, hot rooms). Dress in layers, use fans, keep bedroom cool, moisture‑wicking sleepwear/bedding. Nighttime cooling options: bedside fan, cooling mattress pads/pillows, breathable sheets. Exercise regularly (not right before bed), maintain good sleep hygiene, practice relaxation/breathing techniques for nighttime awakenings. Some women benefit from paced breathing, mindfulness, or CBT for menopausal symptoms. 5) Complementary/alternative interventions — limited evidence Soy/phytoestrogens, black cohosh, and other supplements show mixed results; black cohosh has safety concerns (rare liver toxicity). Discuss before use. Acupuncture has mixed evidence but helps some women. 6) How to choose and what to tell your clinician Important medical history that changes recommendations: breast cancer, history of blood clots or stroke, heart disease, liver disease, migraine with aura, current medications (especially tamoxifen). If you have a uterus and want systemic estrogen, you’ll need progestogen as well (or an IUD). If you had a hysterectomy, estrogen alone is an option. At age 47 you may be perimenopausal (cycles irregular) — this is common; labs (FSH, estradiol) are rarely required unless the diagnosis is unclear. If hot flashes and sleep problems are severe, a primary care doctor or gynecologist can prescribe MHT or a non‑hormonal medication; consider referral to a menopause specialist if complex. Next steps I can help with If you want, tell me: do you still have periods? Any history of breast cancer, blood clots, stroke, heart disease, or migraines with aura? Any current medications (especially tamoxifen) or sleep medications? With that I can suggest a targeted regimen (e.g., a transdermal estradiol patch + micronized progesterone vs. venlafaxine vs. gabapentin) and pros/cons for you.

Mentioned in position 10 of 17

Read full answer with sources →

Public AI visibility history

Daily rank of Effexor on our buyer intent questions, per category. A dash means the engines did not cite Effexor at all that day. This record is permanent.

CategoryJun 11Jun 12Jun 13
Menopause and women's health#36#37#20

TL;DR

Effexor (venlafaxine) is a prescription serotonin-norepinephrine reuptake inhibitor (SNRI) manufactured by Pfizer and widely used off-label to manage vasomotor symptoms such as hot flashes in menopausal women who cannot or prefer not to use hormone therapy. Its official patient resource site lives at effexorvenlafaxine.com. In WellRank's latest index it ranks 12th in the Menopause and women's health category with 8% AI visibility, appearing in AI answers alongside non-hormonal alternatives like Veozah and Brisdelle.

Company Overview

Effexor is a brand-name prescription antidepressant originally developed by Wyeth and now marketed by Pfizer following Pfizer's acquisition of Wyeth in 2009. The drug itself is a small-molecule SNRI available in immediate-release and extended-release formulations, with the extended-release version sold as Effexor XR. Pfizer operates as a publicly traded global pharmaceutical company; the effexorvenlafaxine.com site functions as a patient and prescriber information resource rather than a direct-to-consumer sales channel.

Product Features

  • Effexor XR (venlafaxine extended-release capsules) for once-daily dosing
  • Immediate-release venlafaxine tablets as a generic-available alternative
  • FDA-approved treatment for major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder
  • Widely used off-label for reduction of menopausal hot flashes and night sweats
  • Studied as a non-hormonal option for breast cancer survivors managing vasomotor symptoms

Target Market

Effexor is prescribed primarily in the United States and other markets where Pfizer operates, serving adults with mood and anxiety disorders as its core FDA-approved population. A significant and growing segment of its real-world use covers perimenopausal and postmenopausal women seeking non-hormonal relief from vasomotor symptoms, particularly those with contraindications to estrogen-based therapies. Resources such as womenshealth.gov's menopause treatment guidance and Harvard Health's overview of nonhormonal menopause treatments frequently mention venlafaxine in this context.

Buyer Personas

  • A perimenopausal woman in her late 40s or early 50s who experiences frequent hot flashes and prefers a non-hormonal prescription option recommended by her OB-GYN.
  • A breast cancer survivor whose oncologist has advised against hormone therapy and who is looking for evidence-based vasomotor symptom relief, as discussed in resources like Facing Our Risk's menopause management guide.
  • An adult patient already managing depression or anxiety who receives added benefit from venlafaxine for concurrent menopausal symptoms.
  • A primary care physician or gynecologist researching off-label prescribing options for patients who are not candidates for FDA-approved hormone replacement therapies.

Funding & Performance

Effexor is a product of Pfizer, a publicly traded company (NYSE: PFE). Revenue figures specific to Effexor or venlafaxine are not broken out separately in Pfizer's public filings; the branded Effexor XR lost patent exclusivity years ago and generic venlafaxine now dominates the market. Brand-level sales figures are not publicly disclosed.

Recent Developments

Clinical and regulatory attention around non-hormonal menopause treatments has intensified following the FDA approval of fezolinetant (Veozah) in 2023, which has renewed interest in comparing all available non-estrogen options including venlafaxine. Peer-reviewed research indexed in sources like PubMed Central and ScienceDirect continues to examine venlafaxine's efficacy for vasomotor symptoms relative to newer entrants. Telehealth platforms specializing in women's health, such as Midi Health, have incorporated venlafaxine into their non-hormonal treatment discussions, increasing its digital visibility.

Competitive Landscape

In WellRank's co-mention data, Effexor most frequently appears alongside Veozah (fezolinetant, the first FDA-approved non-hormonal NK3 receptor antagonist for hot flashes), Brisdelle (the only FDA-approved paroxetine formulation for vasomotor symptoms), and Wellbutrin (another non-SNRI antidepressant sometimes considered off-label). Hormone-based options like Vivelle-Dot also appear in the same AI answer sets, reflecting the broader trade-off framing clinicians and patients encounter. Sleep-focused brands Sleepio, Silenor, and Rozerem round out the co-mention set, suggesting AI engines frequently discuss Effexor in threads that cover the full spectrum of menopause-related sleep and mood disruption. The Cleveland Clinic's podcast on managing menopause without hormones illustrates the clinical framing in which these options are compared.

Effexor vs the brands AI recommends alongside it

The real competitive set in Menopause and women's health: brands the engines name in the same answers, ranked on the latest day.

BrandRankAI visibility
Effexor logo
EffexorThis brand
#20
8.3%
Brisdelle logo
Brisdelle

2 shared answers

#18
8.3%
Veozah logo
Veozah

2 shared answers

#17
8.3%
Bonafide Relizen logo
Bonafide Relizen

1 shared answers

#34
8.3%

Email me when overtakes Effexor

One email the day the ranks flip. Nothing else.

User Sentiment

Of the three AI-engine mentions tracked in WellRank's current corpus, two carry a positive tone and one is neutral, with no mixed or cautious mentions recorded. This aligns with the generally favorable clinical literature on venlafaxine's efficacy for vasomotor symptoms, tempered by standard prescriber notes about side effects common to SNRIs. Public sentiment in patient communities tends to reflect satisfaction among women who achieve hot-flash relief, alongside typical concerns about discontinuation syndrome that are well-documented in the medical literature.

Pricing

As a generic-dominant medication, venlafaxine is available at prices that vary widely depending on insurance coverage, pharmacy, and formulation. Branded Effexor XR carries a higher list price than generic venlafaxine; exact figures fluctuate and are not published in a stable, citable form. Patients with insurance typically pay a copay; cash prices for generics are substantially lower and vary by retailer.

Sources cited around Effexor

The sites engines cite in answers mentioning this brand. Win these, win the answer.

Track Effexor weekly

One email a week: rank moves, new competitors, and the answers that changed. No noise.

Work at Effexor? Get your AI Visibility Audit.

See every buyer intent question your customers ask AI, which ones you are losing, who wins them instead, and the exact sources driving those answers. You will finally understand your buyer intent and what Propel would do to win it.

Effexor: AI visibility report | WellRank